Format

Send to

Choose Destination
Clin Sports Med. 2019 Jan;38(1):17-44. doi: 10.1016/j.csm.2018.08.001.

Platelet-Rich Plasma.

Author information

1
Department of Orthopedic Surgery, Stanford University, 450 Broadway Street, Redwood City, CA 94063, USA.
2
Department of Orthopedic Surgery, Stanford University, 450 Broadway Street, Redwood City, CA 94063, USA. Electronic address: jdragoo@stanford.edu.

Abstract

Platelet-rich plasma (PRP) is a promising treatment for musculoskeletal maladies and clinical data to date have shown that PRP is safe. However, evidence of its efficacy has been mixed and highly variable depending on the specific indication. Additional future high-quality large clinical trials will be critical in shaping our perspective of this treatment option. The heterogeneity of PRP preparations, both presently and historically, leads sweeping recommendations about its utility impossible to make. This heterogeneity has also made interpreting existing literature more complicated.

KEYWORDS:

Augmentation; Orthobiologics; Osteoarthritis; PRP; Platelet-rich plasma; Regenerative medicine; Tendinopathy

PMID:
30466721
DOI:
10.1016/j.csm.2018.08.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center